PureTech Health PLC

PureTech Health PLC

PureTech Health PLC

Overview
Date Founded

2015

Headquarters

6 Tide Street,Boston, MA 02210

Type of Company

Public

Employees (Worldwide)

225

Industries

Biotechnology

Company Description

PureTech Health Plc is a cross-disciplinary bio-pharmacy company, which engages in the development of treatment programs for obesity, cognitive disorders, baldness, depression, allergy, and autoimmune. It operates through the following segments: Internal, and Affiliates. The Internal segment is advancing a pipeline fuelled by recent discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. The Affiliates segment is comprised of the programmes within PureTech's Affiliates division. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.

Executives & Employees

Co-Founder

Executive Director, Chief Operating Officer & Company Secretary

Chief Financial Officer

Chief Scientific Officer

Chief Innovation Officer

President & Chief of Business & Strategy

Co-Founder

Co-Founder

Chief Medical Officer

Venture Partner

Board of Directors

Co-Founder at Gurnet Point Capital LLC

Co-Founder at Pulmatrix, Inc. (Inactive)

Co-Founder at PureTech Health PLC

Founder at Kew, Inc.

Lifetime Member of the Board of Directors at The Atlantic Council of the United States

Executive Director, Chief Operating Officer & Company Secretary at PureTech Health PLC

Founder at Kew, Inc.

Physician in Chief Emeritus of Medicine at The Massachusetts General Hospital

Paths to PureTech Health PLC
Potential Connections via
Relationship Science
You
PureTech Health PLC
Owners & Shareholders
Details Hidden

Invesco Perpetual constructs portfolios based on in-house research aiming to identify the investment opportunities most likely to provide the strongest long-term returns. They believe that shareholder activism is fundamental to good corporate governance and while they do not intervene in daily management decisions, they do support general standards for corporate activity and, where necessary, take the initiative to ensure those standards are met. They aim at protecting and enhancing value for clients and investors. The firm's fund managers seek to establish a dialogue with company management to promote decision-making which is in the best interests of shareholders and is in accordance with good corporate governance principles including environmental, social and governance matters. Their UK equity team follows a self-described pragmatic approach with no style bias regarding sectors, stocks or market-cap. Their valuation-orientated approach focuses on absolute returns and risk, allowing the portfolio to capture opportunities over time. In addition to high alpha UK equity, the team also manages small-cap equity and benchmark-relative portfolios. Invesco Perpetual 's European equity team follows a flexible, pragmatic approach focused on delivering consistent outperformance against both the index and the peer group. Fundamental analysis and valuation are central to the investment approach, providing a strong investment discipline that ensures that stocks are purchased only when valuations are appropriate. Their fixed-income team manages retail and institutional accounts, combining macro and bottom-up credit analysis to determine investment opportunities.

Details Hidden

Lansdowne utilizes a variety of methods and strategies to make investment decisions and recommendations. Their investment philosophy generally aims to deliver good annual returns through a rigorous process of fundamental research. The firm manages funds and accounts including fundamental long/short equity funds and traditional equity funds which do not use leverage. The firm currently has strategies namely: developed markets equity; European equity; and global sector equity. For each strategy, Lansdowne identifies investment opportunities through extensive meetings with company managements and their own independent research and analysis. The investment approach is expected to result in relatively concentrated portfolios of positions, but with a focus on maximizing returns relative to risk. The strategies employ the following techniques: short selling; leverage; and derivatives.

Details Hidden

Invesco Perpetual constructs portfolios based on in-house research aiming to identify the investment opportunities most likely to provide the strongest long-term returns. They believe that shareholder activism is fundamental to good corporate governance and while they do not intervene in daily management decisions, they do support general standards for corporate activity and, where necessary, take the initiative to ensure those standards are met. They aim at protecting and enhancing value for clients and investors. The firm's fund managers seek to establish a dialogue with company management to promote decision-making which is in the best interests of shareholders and is in accordance with good corporate governance principles including environmental, social and governance matters. Their UK equity team follows a self-described pragmatic approach with no style bias regarding sectors, stocks or market-cap. Their valuation-orientated approach focuses on absolute returns and risk, allowing the portfolio to capture opportunities over time. In addition to high alpha UK equity, the team also manages small-cap equity and benchmark-relative portfolios. Invesco Perpetual 's European equity team follows a flexible, pragmatic approach focused on delivering consistent outperformance against both the index and the peer group. Fundamental analysis and valuation are central to the investment approach, providing a strong investment discipline that ensures that stocks are purchased only when valuations are appropriate. Their fixed-income team manages retail and institutional accounts, combining macro and bottom-up credit analysis to determine investment opportunities.

Recent Transactions
Details Hidden

The Goldman Sachs Group, Inc., Goldman Sachs & Co. LLC purchase Karuna Therapeutics, Inc. from PureTech Health PLC

Transaction Advisors
Global Coordinator

Advised onPureTech Health PLC issued GBP Ordinary Shares

Underwriter

Advised onPureTech Health PLC issued GBP Ordinary Shares

Advisors & Consultants
Senior Advisor

Co-Founder at Tinkergarten, Inc.

Senior Advisor

President & Chief Executive Officer at Verity BioConsulting LLC

Legal Advisor

Partner at DLA Piper

Clients

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Alphabet, Inc. is a holding company, which engages in the business of acquisition and operation of different companies. It operates through the Google and Other Bets segments. The Google segment includes its main Internet products such as ads, Android, Chrome, hardware, Google Cloud, Google Maps, Google Play, Search, and YouTube. The Other Bets segment consists of businesses such as Access, Calico, CapitalG, GV, Verily, Waymo, and X. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Roche Holding ag Roche Personalised Healthcare – our mission The healthcare landscape is constantly changing. Patients, physicians and payers demand safer, more effective treatments, while investors search after robust and sustainable business models. Growing demand for highly effective, impactful medicines is being driven by an aging population, healthcare and economic pressures. But an influx of new technologies enables Roche to meet this need by offering innovative tests and medicines. These healthcare drivers have led us in one direction – ‘Roche Personalised Healthcare’. At Roche, ‘Personalised Healthcare’ is at the core of our business strategy

Key Stats and Financials As of 2018
Market Capitalization
$931M
Total Enterprise Value
$367M
Earnings Per Share
$-0.12
Revenue
$15.6M
EBITDAMargin
-487.96%
Total Debt
$180M
EBITDA
$-75.9M
Total Equity
$131M
Net Profit
$-32.7M
TEVNet Income
-11.22x
Debt TEV
0.49x
Enterprise Value Sales
23.61x
Three Year Compounded Annual Growth Rate Of Revenue
26.21%
Five Year Compounded Annual Growth Rate Of Revenue
23.51%
Investments
Details Hidden

Sonde Health, Inc. develops voice-based technology platform to monitor and diagnose psychological and physical medical conditions. The company was founded by Michael C. Chen and James Harper in 2015 and is headquartered in Boston, MA.

Details Hidden

The Sync Project, Inc. develops a platform to scientifically measure and harness music to improve health. The company was founded by Marko Ahtisaari, Ketki Karanam and Yadid Ayzenberg and is headquartered in Boston, MA.

Suppliers
Azabu University Tokyo, Japan

University of Tokyo Tokyo, Japan

The University of Tokyo was established in 1877 as the first national university in Japan. As a leading research university, UTokyo offers courses in essentially all academic disciplines at both undergraduate and graduate levels and conducts research across the full spectrum of academic activity. The University aims to provide its students with a rich and varied academic environment that ensures opportunities for both intellectual development and the acquisition of professional knowledge and skills. To learn more about the University of Tokyo, please visit the pages below.

Eli Lilly & Company Hospitals & Patient Services | Indianapolis, Indiana

Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by PureTech Health PLC. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of PureTech Health PLC's profile does not indicate a business or promotional relationship of any kind between RelSci and PureTech Health PLC.